Radiotherapy effects on brain/bone metastatic adenocarcinoma lung cancer and the importance of EGFR mutation test

• DOI: 10.4149/neo_2016_019
• Publication Date: 2015-12-07T14:34:10Z
• Authors: B. L. QU; B. N. CAI; W. YU; F. LIU; Y. R. HUANG; Z. J. JU; X. S. WANG; G. M. OU; L. C. FENG
• Keywords: Lung Neoplasms; Brain Neoplasms; Adenocarcinoma of Lung; Bone Neoplasms; Survival Analysis; 3. Good health; ErbB Receptors; 03 medical and health sciences; 0302 clinical medicine; Mutation; Humans; Neoplasm Staging; Retrospective Studies

This study proposed to retrospectively analyze the efficacy of radiotherapy on brain/bone metastases in patients with stage IV lung adenocarcinoma and evaluate correlation between overall survival after other factors including metastatic sites EGFR mutation status. 115 Stage admitted our center from March, 2011 December, 2013 were enrolled. They presented no solid organs except bone or brain had received prior treatment. 50 test 32 detected as mutant 18 wild-type. Patients treated 40 Gy whole irradiation (WBI) 2 fractions; 30 local 3 fractions fractions. All systemic therapy during 68 targeted therapy.The median solitary metastases, combined 8.50 months, months 9.50 respectively, revealing significant difference (p=0.57). The mutations was 10.25 longer than 8.75 without mutations, 7.50 10.50 11.50 (p=0.91). 36 untested status EGFR-TKI. Among patients, 10 didn't receive therapy; 8 administered Erlotinib 14 Gefitinib 14.5 showing (p=0.11) two drugs. When have been by early radiotherapy, doesn't correlate sites. Radiotherapy could extend for adenocarcinoma. should be performed before treatment disease.